- Current report filing (8-K)
December 17 2008 - 8:56AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 17, 2008
NEUROBIOLOGICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-23280
|
|
94-3049219
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
2000 Powell Street, Suite 800, Emeryville, California
|
|
94608
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(510) 595-6000
|
NOT APPLICABLE
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01 Other Events.
On December 17, 2008, Neurobiological Technologies, Inc. (the Company) issued a press release announcing that
its lead investigational drug, Viprinex, did not pass an interim futility analysis in a clinical trial evaluating
Viprinex for the treatment of acute ischemic stroke. The Company also announced that it has terminated enrollment in
the clinical trial and that it will be analyzing the data from the interim analysis to assess whether Viprinex should
be developed further. A copy of this press release is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated December 17, 2008
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized.
Dated: December 17, 2008
|
|
|
|
|
|
|
NEUROBIOLOGICAL TECHNOLOGIES, INC.
|
|
By:
|
/s/ Matthew M. Loar
|
|
|
|
|
|
Matthew M. Loar
|
|
|
Vice President and Chief Financial Officer
|
2
EXHIBIT INDEX
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated December 17, 2008
|
3
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jul 2023 to Jul 2024